Effects of a losartan-antioxidant hybrid (GGN1231) on vascular and cardiac health in an experimental model of chronic renal failure

This study has been funded by Instituto de Salud Carlos III (ISCIII) through the projects PI13/00014, PI16/00637, PI19/00532” (Co-funded by European Regional Development Fund/European Social Fund “A way to make Europe” (“Investing in your future”)), the ISCIII Retic REDinREN (RD12/0021/1023, RD16/0009/0017) and RICORS2040 (Kidney Disease, RD21/0005/005, RD21/0005 /0019, RD21/0005/0023), Plan de Ciencia, Tecnología e Innovación 2013-2017 y 2018-2022 del Principado de Asturias (GRUPIN14-028, IDI-2018-000152, IDI-2021-000080), Fundación Renal Iñigo Álvarez de Toledo (FRIAT). S.F-V. by a graduate fellowship from the Gobierno del Principado de Asturias (“Severo Ochoa” program, BP20-081), E.G.-C., by a graduate fellowship fron the Universidad de Alcalá de Henares, C.A-M. was supported by REDinREN (RD12/0021/1023, RD16/0009/0017) and RICORS2040 (Kidney Disease) (RD21/0005/0019), S.P. by GRUPIN 14-028, IDI-2018-000152, IDI-2021-000080 and Fundación para la Investigación Biosanitaria de Asturias (FINBA), L.M.-A. by GRUPIN 14-028, PI16/00637, PI17/00384, IDI-2018-000152 and IDI-2021-000080 and N.C.-L. by GRUPIN 14-028, IDI-2018-000152 and IDI-2021-000080.